Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Genocea downgraded to Neutral from Buy at H.C. Wainwright » 06:08
04/29/22
04/29
06:08
04/29/22
06:08
GNCA

Genocea

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis downgraded Genocea Biosciences to Neutral from Buy without a price target. The analyst awaits visibility on the future of GEN-011 with the next update supposed to be in Q4. He cites "the significant lack of visibility at this point" for the downgrade following last night's restructuring announcement.

ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/29/22 Stifel
Genocea downgraded to Hold from Buy at Stifel
04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Downgrade
Genocea downgraded to Hold from Buy at Stifel » 05:00
04/29/22
04/29
05:00
04/29/22
05:00
GNCA

Genocea

/

+

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett downgraded Genocea Biosciences to Hold from Buy with a price target of 16c, down from $4.70, following the announcement that Genocea will be restructuring the business and exploring strategic alternatives. The analyst says he was wrong to be optimistic on GEN-011, and is downgrading shares as he's "not confident this program, nor the business, is viable going forward." Without more balance sheet clarity, viability of the current business model going forward is unlikely, Burnett tells investors in a research note.

ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Hot Stocks
Genocea reduces workforce by 65% as part of restructuring plan » 04:58
04/29/22
04/29
04:58
04/29/22
04:58
GNCA

Genocea

/

+

Genocea announced last…

Genocea announced last night that as it pursues strategic alternatives, the company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in Q2. In light of these developments, the company is reviewing its clinical and research programs to determine an appropriate course of action.

ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Hot Stocks
Genocea engaged advisors to explore strategic alternatives, including sale » 04:58
04/29/22
04/29
04:58
04/29/22
04:58
GNCA

Genocea

/

+

Genocea Biosciences…

Genocea Biosciences announced last night that it has initiated a process to "explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process." Strategic alternatives that will be evaluated include the sale of all or part of the company, merger or reverse merger, the company said in a statement.

ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Hot Stocks
Genocea trading resumes  16:35
04/28/22
04/28
16:35
04/28/22
16:35
GNCA

Genocea

/

+

 
ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Hot Stocks
Genocea trading halted, news pending  16:00
04/28/22
04/28
16:00
04/28/22
16:00
GNCA

Genocea

/

+

 
ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

04/11/22 Baird
Genocea price target lowered to $3 from $8 at Baird
GNCA Genocea
/

+

Over a month ago
Recommendations
Genocea price target lowered to $3 from $8 at Baird » 06:58
04/11/22
04/11
06:58
04/11/22
06:58
GNCA

Genocea

/

+

Baird analyst Colleen…

Baird analyst Colleen Kusy lowered the firm's price target on Genocea to $3 from $8 and keeps an Outperform rating on the shares. The analyst noted they presented initial data at AACR from the Phase 1/2a TITAN study of GEN-011, its neoantigen-targeted adoptive T cell therapy derived from peripheral blood (poster), which showed 4/5 stable disease at the first scan, and 0/5 SD at the second scan. Overall, while response data are below expectations, she thinks ongoing improvements in dosing and manufacturing could result in better activity and she looks forward to additional data in 4Q22.

ShowHide Related Items >><<
GNCA Genocea
/

+

GNCA Genocea
/

+

Hot Stocks
Genocea presents initial data from GEN-011 Phase 1/2a trial » 13:17
04/08/22
04/08
13:17
04/08/22
13:17
GNCA

Genocea

$1.32 /

+0.015 (+1.15%)

Genocea Biosciences…

Genocea Biosciences presents clinical, preclinical, and manufacturing data at the American Association for Cancer Research annual meeting. The presentations include "promising initial data from the TiTAN clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, results demonstrating successful production of GEN-011 using Genocea's PLANET manufacturing process, and new preclinical data on Inhibigens, antigens of suppressive immune responses uniquely identifiable by Genocea's ATLAS platform," Genocea said in a statement. The early results presented at AACR show anti-tumor activity despite the lower intensity regimens and heavily pretreated tumors, the company said. Stable disease was seen at the initial day 57 scan in four of the five patients. While all patients had progressive disease at their day 113 scan, three of the five experienced clear biologic changes after infusion. A patient with metastatic non-small cell lung cancer experienced a 10% reduction in tumor diameters, also with resolution of tumor associated cough. None of the initial patients have experienced dose-limiting toxicities, with no evidence of self-reactivity or autoimmune toxicity. Overall, the range of Grade 2 and Grade 3 treatment emergent adverse events align with expected toxicity from cell therapy regimens.

ShowHide Related Items >><<
GNCA Genocea
$1.32 /

+0.015 (+1.15%)

GNCA Genocea
$1.32 /

+0.015 (+1.15%)

Hot Stocks
Genocea to present initial GEN-011 data at AACR » 07:06
03/10/22
03/10
07:06
03/10/22
07:06
GNCA

Genocea

$1.17 /

+0.105 (+9.86%)

Genocea is conducting the…

Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell therapy candidate. GEN-011 is comprised only of CD8+ and CD4+ T cells, extracted from the patient's peripheral blood and specific for ATLAS-prioritized neoantigens. Patients receive either GEN-011 in multiple fractional doses without lymphodepletion and with intermediate doses of IL-2, or as a single dose after lymphodepletion and with intermediate or high doses of IL-2. Genocea will present clinical, preclinical, and manufacturing data at next month's American Association for Cancer Research Annual Meeting 2022 to be held from April 8-13 in New Orleans. In addition, the company will host an investor call which will span the late-breaking clinical data from the TiTAN clinical trial, results demonstrating success with GEN-011's PLANET manufacturing process, and new preclinical data on Inhibigens, antigens of pro-tumor immune responses uniquely identifiable by Genocea's ATLAS platform.

ShowHide Related Items >><<
GNCA Genocea
$1.17 /

+0.105 (+9.86%)

GNCA Genocea
$1.17 /

+0.105 (+9.86%)

Hot Stocks
Genocea expects cash to support operations into 3Q22 » 07:05
03/10/22
03/10
07:05
03/10/22
07:05
GNCA

Genocea

$1.17 /

+0.105 (+9.86%)

Genocea's existing…

Genocea's existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.

ShowHide Related Items >><<
GNCA Genocea
$1.17 /

+0.105 (+9.86%)

GNCA Genocea
$1.17 /

+0.105 (+9.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.